BP1 overexpression is associated with adverse prognosis in de novo acute myeloid leukemia

Leukemia & Lymphoma
Jing-Dong ZhouJun Qian

Abstract

To investigate DLX4 isoforms expression and their clinical significance in acute myeloid leukemia (AML). DLX4 transcript variant 1 (BP1) expression was significantly up-regulated in AML patients compared with normal controls. However, DLX4 transcript variant 2 (DLX7) was significantly down-regulated in AML patients. Both in the overall AML and the non-M3 AML cohorts, those patients with high BP1 expression (BP1(high)) showed significantly lower rates of complete remission than those with low BP1 expression (BP1(low)). BP1(high) cases had significantly shorter overall survival than BP1(low) cases in the overall AML cohort, non-M3 AML, and cytogenetically normal AML (CN-AML). Multivariate analysis confirmed the independent prognostic value of BP1 expression among both the overall AML cohort and non-M3 AML as well as CN-AML patients. However, we did not observe the impact of DLX7 expression on prognosis in AML patients. Our study reveals that BP1 overexpression serves as an independent risk factor in de novo AML patients.

References

Oct 20, 2001·Best Practice & Research. Clinical Haematology·D Grimwade
Oct 3, 2002·Nature Reviews. Cancer·Cory Abate-Shen
Apr 15, 2005·Breast Cancer Research and Treatment·Yan-gao ManPatricia E Berg
May 12, 2006·American Journal of Medical Genetics. Part a·Petra Kraus, Thomas Lufkin
Sep 28, 2006·Nucleic Acids Research·Marthe-Sandrine Eiymo Mwa MpolloMarie Trudel
Nov 28, 2006·Lancet·Elihu Estey, Hartmut Döhner
Oct 22, 2008·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Arnold M SchwartzPatricia E Berg
Oct 24, 2012·International Journal of Biological Sciences·Lianmei ZhangJunjiang Fu
May 3, 2013·The New England Journal of Medicine·UNKNOWN Cancer Genome Atlas Research NetworkGreg Eley
Dec 5, 2014·Scientific Reports·Naritaka TamaokiKen-ichi Tezuka

❮ Previous
Next ❯

Citations

Jan 13, 2016·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Jing-Dong ZhouJun Qian
May 2, 2019·BMC Molecular and Cell Biology·Rachel K MacKenzieAndrew J Bendall

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.